Dr. Richard Redett, MD
Claim this profileJohns Hopkins University School of Medicine
Studies Unintentional Home Injuries
Studies Skin Tag
3 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Richard Redett, MD is currently running
Face Transplant
for Facial Disfigurement
Background: The human face is critically important for breathing, eating, seeing, and speaking/ communicating, but its most important job may be to look like a human face. Devastating facial deformities often cause affected individuals to avoid human contact and disappear from society. Although current surgical advancements can somewhat restore facial defects, this process often requires many operations and the resulting face only resembles the human face. To date, over 20 face transplants have been performed with highly encouraging functional and aesthetic results, but widespread clinical use has been limited due to the adverse effects of life-long and high-dose immunosuppression needed to prevent graft rejection. Risks include infection, cancer, and metabolic problems, all of which can greatly affect recipients' quality of life, make the procedure riskier, and jeopardize the potential benefits of face transplantation. Study Design: This non-randomized, Phase II clinical trial will document the use of a new immunomodulatory protocol (aka - Pittsburgh Protocol, Starzl Protocol) for establishing face transplantation as a safe and effective reconstructive treatment for devastating injuries/ defects by minimizing maintenance immunosuppression therapy in face transplant patients. This protocol combines lymphocyte depletion with donor bone marrow cell infusion and has enabled graft survival using low doses of a single immunosuppressive drug followed by weaning of treatment. Initially designed for living-related solid organ donation, this regimen has been adapted for use with grafts donated by deceased donors. The investigators propose to perform 15 full or partial human face transplants employing this novel protocol. Specific Aims: 1) To establish face transplantation as a safe and effective reconstructive strategy for the treatment of devastating facial injuries/defects; 2) To reduce the risk of rejection and enable allograft survival while minimizing the requirement for long-term, high-dose, multi-drug immunosuppression. Significance of Research: Face transplantation could help injured individuals recover functionality, self-esteem, and the ability to reintegrate into family and social life as "whole" individuals. This protocol offers the potential for minimizing the morbidity of maintenance immunosuppression, thereby beneficially shifting the risk/benefit ratio of this life-enhancing procedure and enabling a wider clinical application of face transplantation.
Recruiting1 award Phase 2
Uterus Transplant
for Infertility
This research study will use uterus transplantation to treat uterine factor infertility, also known as the inability to bear children due to not having a uterus. The purpose of this study is to enable women seeking genetically-related children and the childbearing experience to experience pregnancy and birth a child. In this study, living donors will undergo surgery to give the donor's uterus to another woman. The woman who receives the transplant will take immunosuppression to keep the uterus and herself healthy. Because taking immunosuppressive medicine has side effects, uterus transplantation is intended to be temporary, lasting about 5 years. The goals of the study are successful pregnancy and the birth of one, and possibly two, healthy babies per transplant patient. The uterus is to be removed and immunosuppression stopped following the birth of a child. Offspring are delivered by Caesarian section, at which time the transplant may also be removed. Transplant candidates must have fertilized, frozen (cryopreserved) embryos at a Johns Hopkins facility before undergoing transplantation. Transplant candidates will be asked to identify candidates' potential uterus donor. Altruistic donors, or women who want to donate without knowing a potential recipient, may also participate. All potential donors will be screened to see if the donors are a good match for a recipient and are healthy enough to have the donation surgery. Study Duration: * Uterus Donors: Screening through about 12 months following the transplant operation. * Uterus Recipients: Recipients may have the uterus for about 5 years. After the transplant is removed, the study team will ask for yearly follow-ups for another 5 years. * Children born from transplanted uteruses: The study team asks to follow offspring yearly through age 21 years.
Recruiting1 award Phase 2 & 34 criteria
More about Richard Redett, MD
Clinical Trial Related12 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Richard Redett, MD has experience with
- Tacrolimus
- Pittsburgh Protocol/Starzl Protocol
- Azathioprine
- Uterine Allotransplantation
- Monoclonal Antibody
- Penile Allotransplantation
Breakdown of trials Richard Redett, MD has run
Unintentional Home Injuries
Wounds and Injuries
Facial Injury
Appearance
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Richard Redett, MD specialize in?
Richard Redett, MD focuses on Unintentional Home Injuries and Skin Tag. In particular, much of their work with Unintentional Home Injuries has involved treating patients, or patients who are undergoing treatment.
Is Richard Redett, MD currently recruiting for clinical trials?
Yes, Richard Redett, MD is currently recruiting for 3 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Richard Redett, MD has studied deeply?
Yes, Richard Redett, MD has studied treatments such as Tacrolimus, Pittsburgh Protocol/Starzl Protocol, Azathioprine.
What is the best way to schedule an appointment with Richard Redett, MD?
Apply for one of the trials that Richard Redett, MD is conducting.
What is the office address of Richard Redett, MD?
The office of Richard Redett, MD is located at: Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 United States. This is the address for their practice at the Johns Hopkins University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.